Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's EV-to-FCF or its related term are showing as below:
FRA:O15'
s EV-to-FCF Range Over the Past 10 Years
Min: -37.47 Med: -1.18 Max: 1.24
Current: -37.47
During the past 4 years, the highest EV-to-FCF of InSilico Medicine Cayman TopCo was 1.24. The lowest was -37.47. And the median was -1.18.
FRA:O15's EV-to-FCF is ranked worse than 100% of 1595
companies
in the Software industry
Industry Median: 15.72
vs FRA:O15: -37.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
InSilico Medicine Cayman TopCo (FRA:O15) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
InSilico Medicine Cayman TopCo's PE Ratio (TTM) for today is calculated as:
InSilico Medicine Cayman TopCo's share price for today is €5.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
InSilico Medicine Cayman TopCo EV-to-FCF Related Terms
InSilico Medicine Cayman TopCo EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo EV-to-FCF vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's EV-to-FCF falls into.
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-68.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (FRA:O15) has a EV-to-FCF of -37.84 as of Aug. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 1595 companies in the Software industry.
Is InSilico Medicine Cayman TopCo's EV-to-FCF too high?
InSilico Medicine Cayman TopCo's current EV-to-FCF is -37.84. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 1595 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's EV-to-FCF compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 1595 companies for EV-to-FCF. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median EV-to-FCF is 15.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Software company?
The median EV-to-FCF among Software companies is 15.72, based on 1,595 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median EV-to-FCF is 15.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current EV-to-FCF is -37.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current EV-to-FCF of -37.84. The current EV-to-FCF is -37.84. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current EV-to-FCF is -37.84 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
